Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma

Figure 3

Plasma concentrations of angiotensin system peptides and angiogenic hormones over time are shown. The data points represent median values for the pretreatment (Time 0) and posttreatment blood draws. The 4-hour and day 22 posttreatment Ang-(1-7) levels were increased over baseline (). Standard error bars are shown.